Hyo-Soo Kim, ACC 2023: HOST IDEA trial – Short-term dual antiplatelet therapy non-inferior to 12 Months after PCI with third-generation drug-eluting stents
The goal of dual antiplatelet therapy (DAPT) is to reduce the risk of stent thrombosis, a potentially life-threatening complication that can occur when blood clots form in the stent. In this touchCARDIO interview, we speak with Prof. Hyo-Soo Kim (Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea) highlights the findings from the HOST IDEA trial investigating the non-inferiority of 3-6 months of DAPT compared to 12 months after percutaneous coronary intervention (PCI) using third-generation drug-eluting stents (DES) with ultrathin struts and advanced polymer technology.
The abstract entitled ‘Comparison Of 3-month Versus 12-month Dual Antiplatelet Therapy After Coronary Intervention Using The Contemporary Drug-eluting Stents With Ultrathin Struts And Advanced Polymer Technology: The Host-idea Randomized Clinical Trial‘ was presented at ACC.23 Together With WCC (ACC.23/WCC) in New Orleans, 4–6 March 2023.
Interviews in this series:
Prof. Hyo-Soo Kim discusses guidelines for the use of short-term dual antiplatelet therapy after coronary intervention.
- What are the aims, design and eligibility criteria of the HOST IDEA study? (0:23)
- What were the primary and secondary endpoints and how well were they achieved? (2:23)
- What were the objectives and findings of the subgroup analyses? (5:32)
- How will these findings be used to inform future treatment decisions? (7:38)
Disclosures: Hyo-Soo Kim has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of ACC 2023
Access more content on dual antiplatelet therapy
Share this Video
Related Videos In Interventional Cardiology
Gregg Stone, ACC 2023: Transcatheter edge-to-edge repair for functional mitral regurgitation in heart failure
Transcatheter edge-to-edge repair (TEER) is a minimally invasive procedure that can effectively treat functional mitral regurgitation in heart failure patients. Compared to traditional surgical approaches, TEER offers benefits such as reduced hospital stay, lower risk of bleeding and infection, and faster recovery time. Additionally, TEER has been found to improve symptoms and quality of life […]
Gregg Stone, ACC 2023: COAPT trial results – Transcatheter edge-to-edge repair with MitraClip device for functional mitral regurgitation in heart failure
The COAPT trial investigated the use of the MitraClip a novel device for patients with secondary mitral regurgitation, a condition in which blood leaks backward through the mitral valve into the left atrium of the heart. In this touchCARDIO interview Dr Gregg Stone (Mount Sinai Heart Health System, New York City, NY, USA) discusses the […]
Hyo-Soo Kim, ACC 2023: Guidelines for the use of short-term dual antiplatelet therapy after coronary intervention
The guidelines for the use of short-term dual antiplatelet therapy (DAPT) after coronary intervention vary depending on the patient’s clinical situation and the type of intervention performed. In this touchCARDIO interview, we speak with Prof. Hyo-Soo Kim (Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea) to discuss the current guidelines for the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!